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Chromosome studies of human melanocytic tumors have demonstrated non-random karyotypic abnormalities of
chromosomes 1, 6, 7, 9, and 10. These visible genetic alterations may provide clues to the location of oncogenes and
suppressor genes involved in the development of lesions from benign nevus to metastatic melanoma, and to the
mechanisms by which the function of these genes is altered. To date, however, none of the specific growth regulatory genes
important in this neoplastic progression has been identified, with the possible exception of the erbB oncogene in the later
stages. Recent results in other human tumors do suggest, however, that the combined cytogenetic and molecular genetic
approach will soon lead to the recognition of a number of important genes, both inherited and somatically altered, and that
significant clinical applications will follow. J Invest Dermatol 100:254S–258S, 1993
The neoplastic system affecting epidermal melanocytes and leading to
malignant melanoma is a valuable model for the study of the sequential
steps involved in tumor progression. The lesions of interest usually occur
on the skin and are therefore accessible for early diagnosis and, when
surgically removed, karyotypic analysis.
The common acquired melanocytic nevus, a focal proliferation of
structurally normal cells, is often the first step in the progression of this
disease, followed by the dysplastic nevus with abnormal hyperplasia of
melanocytes and atypia, and finally evolution to primary melanoma, first
as the radial growth phase, which does not have the capacity to
metastasize, and then as the vertical growth phase (VGP), which is
capable of progressing to metastatic disease. This stepwise progression
allows the cytogeneticist to obtain karyotypic data from lesions that are
premalignant through to primary tumors and their subsequent metastases.
Until recently, little has been published on the cytogenetics and
related molecular genetics of solid tumors, and most of the limited data
have been derived from advanced lesions, often metastases. These
usually contain many chromosomal alterations, making it difficult, if not
impossible, to determine which might have been the primary or initial
change. There are even fewer data on early lesions, which often have
very few dividing cells, making it necessary to establish them in tissue
culture before a high enough mitotic index is present to permit karyotypic
analysis.
Despite these limitations, cytogenetic studies have begun to provide
useful clues to the sequential somatic genetic changes involved in the
development of a number of human solid tumors. Most notable have
been the findings in colon carcinoma, where detailed molecular studies
of chromosomal abnormalities have helped lead to the recognition of a
number of ‘‘oncogenes’’ and suppressor genes associated with various
stages of progression of this neoplasm [1]. Similar investigations are
currently under way for certain central nervous system tumors, as well as
for the common malignancies of the breast and lung [2].
In melanocytic lesions, we and others have identified nonrandom
karyotypic changes involving chromosomes 1, 6, and 7 (Fig 1), as well as
less common alterations of chromosomes 9 and 10 [3–7]. Figure 2 is an
attempt to indicate associations between these cytogenetic abnormalities
(as well as changes in specific genes) and particular stages of melanoma
development. This sequential pattern needs to be confirmed by more
extensive studies, but it at least provides a conceptual framework for
researchers investigating these phenomena.
In the following sections, we will attempt to summarize the
information that supports this diagrammatic representation, indicating
the current state of knowledge concerning various nonrandom karyotypic
alterations in melanocytic tumors, and the very limited data on the
growth regulatory genes involved.
CHROMOSOME 1
Of the 58 advanced melanomas in our series, 53 had one or more
alterations involving chromosome 1, with most of these being deletions
or translocations involving the region lpl2-22 [3]. Other investigators
have also reported nonrandom involvement of chromosome 1, and when
the breakpoints are specified, they have most often been in the same
region that we have noted [3–7]. We have also reported a t(l;19)
translocation involving the proximal portion of lq in three cases of
advanced melanoma [8].
It is of interest that the oncogene N-ras and the gene for the b-subunit
of nerve growth factor (NGF) have been mapped to the region Ip22 [9].
Alterations in NGF have not yet been reported in melanoma, but in four
of 30 melanoma cell lines tested, an activated N-ras gene with
transforming ability in the NIH/3T3 assay was extracted [10].
Dracopoli et al, using restriction fragment length polymorphism
analysis, reported loss of heterozygosity (LOH) for lp in 15 of 35 (43%)
melanomas and in 11 of 21 (52%) melanoma cell lines that they studied
[11,12]. No consistent single region of loss was seen, but the highest
frequencies of LOH were found on the distal region of lp.
Abnormalities of chromosome 1 have also been reported in other
human solid tumors, such as carcinoma of the testis, cervix, ovary, and
breast, and in hematopoietic neoplasms [13]. In most of these tumors, the
breakpoints occurred in the region of the centromere between Ipl2 and
ql2. Malignant melanomas, however, have deletions and translocations
in a more distal region of lp, suggesting that a gene or genes here may be
important in progression of this disease.
Genetic studies of families have also indicated linkage between the
incidence of melanoma and the Rh gene, which has been mapped to the
region Ip32–36, even more distal than the segment identified in
karyotypic investigations [14]. Bale et al [15] reported co-segregation
of the occurrence of familial dysplastic nevus syndrome (DNS) with the
presence of marker loci at Ip36, suggesting that, at least in some families,
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there is a gene on the terminal region of lp that is involved in the
inheritance of familial disease; however, several other reports, involving
other families, found evidence against linkage of DNS to a locus at
chromosome band Ip36 [16-18]. It may be that either diagnostic or
genetic heterogeneity is to blame for the discrepancy between these
findings and the study of Bale et al [15]. The phenotype of DNS is highly
variable and subject to skin type and amount of UV exposure. People
with DNS may have from a few to hundreds of dysplastic nevi, making it
difficult to arrive at a definitive diagnosis. An alternative explanation for
the difference seen between these populations is that DNS may exhibit
genetic heterogeneity. More studies will be needed to determine which,
if either, of these explanations is correct [19].
Finally, with regard to chromosome 1 and melanoma, we reported a
nonrandom translocation involving the long arm of chromosome 1 (1q)
in three cases of advanced melanoma [8]. To our knowledge, this is the
only nonrandom chromosome translocation so far reported for this
disease. A t(1;19)(q12;p13) translocation was seen in three tumors, with
the der(1;19) chromosome representing an extra dose of 1q in each case.
The breakpoint on 1q was unusual in that it was in a heterochromatic
region and not in the region of any known growth-regulatory genes.
A t(1;19)(q23;p13) translocation is also seen in a subset of childhood
pre-B-cell acute leukemias [20,21]. Although the regions involved on
chromosome 1 differ, the 19p13 breakpoint appears to be very similar. It
is interesting to note that a gene that codes for a transcriptional activator,
PBX, has been mapped to 19p13. The breakpoint of the t(1;19)(q23;p13)
translocation in pre-B-cell leukemia has been cloned, and it was found
that the E2A gene on 1q23, which codes for a DNA binding protein, fuses
with the PBX gene on 19p13 [20,21]. The resulting chimeric protein is
constitutively expressed in leukemic pre-B cells, whereas the PBX gene is
not expressed in normal pre-B cells. The t(1;19) translocation therefore
alters the transcriptional status of the cell. A similar mechanism might
also be responsible for disrupting normal transcription in melanocytic
tumors, but nothing has yet been reported about the possible genes
involved.
CHROMOSOME 6
The most common abnormalities of chromosome 6 seen in melanoma
are deletions in the long arm, most often in the region 6q12-25 [3–7]. The
short arm seems to be preferentially retained, often as an isochromosome
(iso6p). Sozzi et al transfected a melanocyte cell line having a normal
karyotype with a retrovirus containing H-ras and c-myc oncogenes and
induced all of the features of transformation. The only structural
abnormality found was an iso6p [22].
Several stimulatory oncogenes have been mapped to regions on 6q,
including c-myb and c-ro5 [23,24], but none have been shown to be
commonly involved in melanocytic tumors. Linnenbach et al [25], in a
study of 30 melanoma cell lines from 28 patients, found no alterations in
c-ros and found only a single alteration in tnyb. In 22 lines evaluated for
changes in myb, one line from a VGP tumor, with breakpoints at 6q22
and 6q25, showed results consistent with a structural rearrangement of
myb, which maps to 6q22. Albino [26] reported finding a rearranged
myb in two of 56 melanoma lines screened, and Meese et al [27] found
two of 15 lines with possible rearrangements in the c-myb flanking
sequences.
Trent et al [28], by means of microcell hybrids, introduced a normal
chromosome 6 into melanoma cell lines and showed that the resulting
microcell hybrids lost their capability to form tumors in nude mice. The
loss of chromosome 6 from the microcell hybrids resulted in a reversion
to tumorigenecity of the cells in mice. Also, a recent report from Milliken
et al [29] describes LOH for loci on the long arm of chromosome 6 in
melanoma. The regions most frequently lost were 6q22–23 and 6q24–27.
These results suggest that the relevant genes on chromosome 6 may be
one or more tumor suppressor genes that are still unidentified.
CHROMOSOMES 7 AND 10
As mentioned earlier, few studies have been done on the chromosomal
changes in early lesions. Some limited data indicate that the chromo-
somal region 10q24–26 may be involved in the early stages of
melanocytic neoplasia. In a study by Richmond et al [30], one of the
two compound nevi with structural changes had a translocation
involving the region 10q24. One of the two dysplastic nevi with
abnormal clones in our series had as its only change a t(9;10)(p24;q24)
Figure 1. Karyotype of a cell line from a metastatic melanoma containing
numerous chromosomal abnormalities typically seen in advanced lesions.
In particular, note the involvement of the short arm of chromosome 1, an
abnormal chromosome 6, and extra copies of chromosome 7.
Figure 2. Stages of melanocytic tumor development and associated chromosome and gene alterations.
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translocation in all of the cells examined [31]. Furthermore, two of the
three relatively early melanomas in our series that contained areas of
both radial growth phase and VGP showed involvement of chromosome
10. One had a t(10;?)(q26;?) translocation, and the other had lost copies
of chromosome 10. Also, in the only case of advanced melanoma we
studied that had only a single cytogenetic abnormality, we observed a
three-way rearrangement involving chromosomes 5, 6, and 10, with the
region 10q23–25 being involved.
In addition to these structural rearrangements, loss of copies of the
entire chromosome 10 has been reported in the late stages of
melanocytic neoplasia, often accompanied by a gain of copies of
chromosome 7. Extra dosage of all or part of chromosome 7 was present
in 36 of the 58 advanced melanomas in our series [3]. Twenty-two of the
36 had extra copies of the whole chromosome, with 10 of these also
losing copies of chromosome 10. Jenkins et al [32] correlated cytogenetic
loss of chromosome 10 with LOH studies in gliomas and showed that
12 of 13 tumors with loss of chromosome 10 also had LOH for 10,
whereas another 15 tumors showed LOH on chromosome 10 but no
detectable cytogenetic loss of material. Therefore, our series may actually
have a higher percentage of gain of chromosome 7 and concurrent loss of
chromosome 10. These parallels in genetic changes between gliomas
and melanomas may reflect the origin of melanocytes from the neural
crest. It might be expected that some of the same growth-regulatory genes
would be involved in the development of central nervous system tumors
and of pigmented lesions, but until more of the specific genes are
identified, this possibility must remain speculative.
The presence of extra copies of chromosome 7 in melanoma
appears to be associated with the expression of the epidermal growth
factor (EGF) receptor [33], which has been mapped to 7p12–13 [34]. A
portion of the EGF receptor gene is coded for by the human proto-
oncogene c-erbB [35]. Increased copies of chromosome 7 have also been
correlated with over-expression of the erbB oncogene in human
glioblastoma cell lines [36]. The level of over-expression of the erbB
oncogene in these glioblastoma lines is even higher than what would be
expected from the number of copies of chromosome 7, but neither in
these tumors nor in the melanomas is it clear whether the increased
expression of EGF receptor involves a structurally altered gene. In any
event, this is one of the very few instances in human neoplasia where
extra copies of a chromosome have been directly correlated with a
cellular change that may be contributing to the proliferative advantage of
the neo-plastic cells.
Themet oncogene, which is also located on chromosome 7 (q31–32),
was not shown to be over-expressed in a panel of seven glioblastoma cell
lines with over-expression of erbB [37]. Henn et al therefore postulated
that there is differential regulation of the met and erbB oncogenes,
possibly by means of a transacting suppressor gene that regulates the
expression of erbB and, when lost, allows over-expression of erbB [37],
This gene could be located on a chromosome with reduced copy
number, such as chromosome 10.
OTHER CHROMOSOMAL CHANGES
Less consistent cytogenetic alterations have also been reported in
malignant melanoma. Abnormalities of chromosome 9, particularly of
the short arm, have been reported [4-7]. Also, a report by Dracopoli et al
[11,12] indicated loss of heterozygosity of the region 9p24-pter in six
metastases from the same patient. As a result of these observations, Bale
and Dracopoli performed linkage analysis between the locus of
malignant melanoma/dysplastic nevus syndrome and a marker on 9p in
four families with hereditary malignant melanoma [38]. No evidence of
linkage was found, so they suggested that the reported loss of
heterozygosity of 9p is a secondary rather than a primary event in
melanocytic transformation; or, alternatively, that loci involved in
familial melanoma may differ from those involved in sporadic cases of
melanoma. Loss of 9p loci is also seen in glial tumors [39,40].
There have been a few reports of structural rearrangements involving
the short arm of chromosome 11 [7], but these are less consistent.
Ha-ras-1 has been mapped to 11lp, but segregation analysis of Ha-ras-1
alleles and restriction fragment length polymorphisms of four loci on lip
in families with the dysplastic nevus syndrome failed to show any
association of a predisposition to melanoma or dysplastic nevi with the
Ha-ras-1 locus or the segment of chromosome 11 to which it has been
mapped [41].
OTHER ONCOGENES AND SUPPRESSOR GENES
To date, there have been only a few extensive molecular studies of
melanoma to determine which previously known oncogenes may be
involved in melanocytic transformation, and except for involvement of
p53, and perhaps the ras oncogene family, the results have been
inconclusive. As mentioned earlier, Linnenbach et al [25], using the
Southern blotting technique, analyzed 30 cell lines from 28 melanoma
patients, with molecular probes for both growth-related genes and genes
near frequently involved chromosomal breakpoints. These included
oncogenes such as met, N-ras-2, K-ras-2, pitn-1, ros, int-l, raf-l, A-raf-1,
Her-2-neu, bcl-2, sis, p53, myc-N, myc-L, myc, and myb; genes
encoding insulin-like growth factor (IGF)-l, IGF-2, NGF-B, EGF, and
platelet-derived growth factor-A; genes encoding receptors for IGF-1,
NGF, EGF, and platelet-derived growth factor; and other genes involved
in growth regulation, such as protein kinase C (PKC)-a, PKC-b and PKC-g.
The only abnormalities found were the previously mentioned rearrange-
ment of myb in one line and a deletion involving the gene for PKC-a. Of
note, an abstract by Pedersen and Wang [42] indicated high frequencies
of genomic alterations of N-ras, N-myc, c-raf-1, and c-abl in 11 cell lines
from eight metastatic melanomas, but no details were provided. These
four genes were also included in the Linnenbach et al study [25] and
were not found to be altered.
Other laboratories have also investigated the involvement of ras
in melanomas, with conflicting results. Shukla et al [43] detected
point mutations in K-ras in 25% of the malignant melanoma tumors
they studied using the polymerase chain reaction. K-ras mutations were
seen at all stages of melanocytic tumor progression from benign nevi to
nodal metastases. Albino et al [10] reported that 24% of cultured
malignant melanomas have mutated ras genes, with N-ras being mutated
10 times as frequently as Ha-ras. K-ras was not examined in this series;
however, only 5–6% of non-cultured primary and metastatic tumors had
ras mutations. Gerhard et al [41], in a study of tumors from 58 patients
with sporadic malignant melanoma, found that the distribution of
mutated ras genes in those tumors did not differ from that in a normal
population.
Mutations of the p53 tumor suppressor gene have been identified in a
variety of human solid tumors. This gene has been mapped to 17pl3, and
although cytogenetic alterations of this region have not been reported in
melanoma, a recent study by Stretch et al [44] suggests that submicro-
scopic changes in the p53 suppressor gene may be a relatively common
component of melanocytic tumor development. Mutations of the p53
protein were detected in 85% of the surgical specimens analyzed. These
included both primary and metastatic tumors.
This observation with respect to p53 suggests the possibility that this
or other tumor suppressor genes (e.g., the retinoblastoma gene, Rb) may
in some instances represent an inherited defect. As possible indirect
evidence, some investigators have observed that patients with malignant
melanoma seem to be at higher risk for developing other types of cancer.
Gutman et al [45] studied 370 patients with histologically confirmed
malignant melanoma and found that they had a significant pre-
disposition to developing second tumors. The relative risk for a second
malignancy was highest for breast cancer in women.
Garber et al [46] suggested a possible relationship between
melanoma and soft tissue sarcoma. Both are relatively rare diseases,
accounting for 3% and less than 1%, respectively, of all malignancies in
the U.S. population. Seven patients (one of whom had the familial
dysplastic nevus syndrome) developed both melanoma and sarcoma,
with these tumors presenting either at the same time or sequentially, and
three of the seven patients had at least one other malignancy in addition
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to melanoma and sarcoma; however, analysis of similar data from
Denmark failed to show an association between melanoma and soft
tissue sarcomas [47]. Melanoma has also been reported as occurring in
survivors of heritable retinoblastoma. Traboulsi et al [48] calculate that
malignant melanoma accounts for 7% of second malignant neoplasms in
retinoblastoma survivors. These occurred both in and away from the field
of irradiation and also in patients who did not receive radiation therapy
for their retinoblastomas.
Melanoma has been reported as one of the tumor types associated
with the Li-Fraumeni syndrome, a rare autosomal-dominant familial
cancer syndrome in which germ line p53 mutations have been detected
[49]. It would therefore be of interest to study patients with the
familial dysplastic nevus syndrome to discover whether one could
detect constitutional mutations of either p53 or the Rb gene in these
families.
GENETIC INSTABILITY
There is also some evidence that both peripheral blood lymphocytes and
fibroblasts from patients with DNS may show increased chromosomal
instability. The studies have involved both irradiated and unirradiated
cells [50–53]. Elevated levels of chromosomal abnormalities in cells from
patients, as opposed to normal subjects, have led to the suggestion that
DNS may be an ‘‘instability’’ syndrome, but more extensive studies are
needed to confirm this hypothesis.
CONCLUSIONS
The data summarized in the previous sections indicate, as with most
human tumors, that the full development of malignant melanoma
apparently results from multiple sequential somatic genetic alterations
in the neoplastic cells, many of them recognizable as chromosomal
alterations. Both the cytogenetic studies and the limited molecular
investigations indicate that some of the growth-regulatory genes involved
in this process are previously known ‘‘oncogenes’’ (e.g., ras, p53, erbB)
but also suggest that a significant number of yet unidentified genes are
also important. The data also support the view that the relevant genes
include both stimulatory ‘‘oncogenes’’ and tumor-suppressor genes, as
well as, presumably, genes and gene products associated with the
capacity of the fully malignant melan-ocytic cells to invade and to
metastasize. In some families, an inherited gene may also contribute, but
it is not clear whether this represents a tumor-suppressor gene or,
perhaps, a gene associated with ‘‘genetic instability,’’ which makes cells
more likely to undergo somatic genetic alterations.
In general, these findings parallel those that have been developed
over the past decade in studies of human hematopoietic tumors and,
more recently, the common human solid malignancies. As indicated
earlier, such studies have been particularly productive in investigations of
the developmental stages of human colon cancer, and similar work is
under way in central nervous system tumors and in breast, lung, and
other malignancies. In all of these circumstances, cytogenetic studies
have provided clues to the location of important genes and suggested
mechanisms by which their function may be critically altered. Although a
handful of previously known oncogenes and suppressor genes have been
identified through this approach, it appears that most of the specific genes
associated with nonrandom karyotypic alterations remain to be
identified.
Of note, in contrast to the known oncogenes, it seems that many of
these previously unknown growth-regulatory genes involved in human
tumorigenesis may prove to be lineage specific with respect to their
oncogenicity or at least restricted in this regard to a limited number of
cell types. For example, the abnormalities of chromosomes 7 and 10,
which are common in melanoma, apparently also occur nonrandomly
only in other tumors of neural crest origin. Although the chromosome 7
abnormality may involve the erbB oncogene, it appears that the
cytogenetic alterations of these two chromosomes will also ultimately
prove to be associated with additional stimulatory oncogenes and/or
suppressor genes that are still unidentified.
Clearly, we have learned much about the fundamental nature of
neoplasia in the past decade, but we have also come to recognize how
much remains to be learned. It appears that the critical genetic events in
human malignancies will show considerable variation from tumor to
tumor, making it difficult to generalize from any one type of neoplasm.
As we carefully dissect the sequence of events in melanoma, as well as
other malignancies, cytogenetics will continue to provide valuable
guideposts to the genes involved, and eventually, from the detailed
information that emerges will come improved approaches to diagnosis,
prognosis, and, ultimately, specific therapy.
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